Welcome to our dedicated page for Innoviva SEC filings (Ticker: INVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Innoviva, Inc. filings document a Nasdaq-listed common-stock issuer with a royalty healthcare portfolio, Innoviva Specialty Therapeutics operations, and strategic healthcare investments. Form 8-K reports furnish operating results and financial condition, including royalty revenue, IST net product sales, product-portfolio developments, fair-value changes in investments, and capital allocation activity.
Proxy and annual-meeting filings cover board elections, advisory executive-compensation votes, auditor ratification, and equity incentive plan approvals. The record also identifies the company’s common stock, par value $0.01 per share, traded under INVA on the Nasdaq Global Select Market.
Innoviva, Inc. Chief Accounting Officer Marianne Zhen reported a routine tax-related share disposition. On February 20, 2026, 2,460 shares of common stock were withheld at $23.39 per share to cover income tax obligations tied to vesting of prior equity grants, leaving her with 45,877 directly owned shares.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation reported a significant ownership stake in Innoviva, Inc. common stock. As of 12/31/2025, they beneficially owned 4,210,172 shares, representing 5.63% of the outstanding common stock, with sole voting and dispositive power over these shares.
The firms state the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Innoviva. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and sale proceeds from these shares.
Dimensional Fund Advisors LP has filed an amended Schedule 13G reporting beneficial ownership of 4,360,401 shares of Innoviva Inc. common stock, representing 5.8% of the class as of 12/31/2025. Dimensional reports sole voting power over 4,255,642 shares and sole dispositive power over 4,360,401 shares.
The shares are held by a series of funds and accounts it advises or manages, and Dimensional states that all securities are owned by these funds. Dimensional disclaims beneficial ownership of the securities beyond what is required for Section 13(d) reporting. It also certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Innoviva.
Innoviva, Inc. (INVA) reported insider equity activity for its Chief Financial Officer, Stephen Basso, on a Form 4. On November 15, 2025, he acquired 604 shares of common stock at $0 under the Innoviva Employee Stock Purchase Plan. On November 20, 2025, 237 shares of common stock were withheld by Innoviva at $21.16 per share to cover income tax obligations tied to the quarterly vesting of previously granted equity awards. After these transactions, he directly owned 51,257 shares of Innoviva common stock.
Innoviva, Inc. (INVA) reported a routine insider transaction by its Chief Accounting Officer, who filed a Form 4 for a tax-related share withholding. On 11/20/2025, 992 shares of common stock were withheld by Innoviva at a price of $21.16 per share to cover income tax obligations tied to the quarterly vesting of previously granted employee equity awards. After this withholding, the reporting person beneficially owned 48,337 shares of Innoviva common stock directly.
Innoviva, Inc. (INVA) reported an insider equity award. The company’s Chief Financial Officer filed a Form 4 showing acquisition of 27,609 shares of common stock on 11/03/2025 at $18.11 per share, bringing holdings to 50,890 shares directly.
The award is a time-vested RSU: 25% vests on November 20, 2026, with the remainder vesting in 12 substantially equal quarterly installments thereafter, subject to continued service. Vesting may accelerate upon a qualifying change in control or an involuntary termination within 24 months following such a change, as approved by the Board’s Compensation Committee.
Innoviva, Inc. (INVA) reported insider equity activity. The reporting person acquired 110,436 shares of common stock at $18.11 on November 3, 2025, noted as a time‑vested RSU grant. 25% vests on November 20, 2026, with the remainder vesting in 12 substantially equal quarterly installments, subject to continuous service, with accelerated vesting upon specified change‑in‑control conditions.
The filing also shows 1,860 shares acquired at $0 under the Employee Stock Purchase Plan on May 15, 2025. Following the reported transactions, the reporting person beneficially owned 162,276 shares directly.
Innoviva, Inc. reported stronger Q3 2025 results. Total revenue for the three months ended September 30, 2025 was $107.8 million, up from $89.5 million a year ago, driven by $59.9 million in royalty revenue and $47.3 million in net product sales. Net income rose to $89.9 million (diluted EPS $1.08) from $1.2 million (diluted EPS $0.02) in Q3 2024, aided by gains in the fair values of investments.
Year-to-date through Q3 2025, revenue reached $296.7 million with net income of $107.0 million. Cash and cash equivalents were $476.5 million as of September 30, 2025, supported by $142.4 million in operating cash flow for the nine-month period. The company eliminated its current balance on the 2025 convertible notes through conversions totaling $192.5 million to common stock, while long-term debt stood at $257.4 million. Common shares outstanding were 74,769,062 as of October 31, 2025.
Innoviva, Inc. (INVA) furnished an 8-K announcing its quarterly results press release. On November 5, 2025, the company provided a press release covering results for the quarter ended September 30, 2025, attached as Exhibit 99.1. The disclosure under Item 2.02 is furnished, not filed, and is not subject to Section 18 liabilities, nor incorporated by reference unless specifically stated.
Bank of Nova Scotia filed an amended Schedule 13G reporting beneficial ownership of 2,179,005 shares of Innoviva, Inc. common stock, representing 3.37% of the class as of the reporting event date 09/30/2025. The filing shows the bank has sole voting and sole dispositive power over all reported shares and does not report shared voting or dispositive power. The filing identifies the filer as a parent holding company organized in Canada and includes a certification about comparable foreign regulatory oversight. No larger group affiliation, transfers on behalf of others, or ownership above 5% are reported.